17,847 results
Search Results
2. Comparison of paper spray mass spectrometry analysis of dried blood spots from devices used for in-field collection of clinical samples.
- Author
-
Yannell KE, Kesely KR, Chien HD, Kissinger CB, and Cooks RG
- Subjects
- Blood Specimen Collection instrumentation, Blood Specimen Collection methods, Dried Blood Spot Testing instrumentation, Drug Monitoring instrumentation, Equipment Design, Humans, Limit of Detection, Paper, Tandem Mass Spectrometry instrumentation, Antineoplastic Agents blood, Benzamides blood, Dried Blood Spot Testing methods, Drug Monitoring methods, Imatinib Mesylate blood, Piperazines blood, Tandem Mass Spectrometry methods
- Abstract
Paper spray (PS) is an ambient ionization technique applicable to ionizing analytes from untreated dried biofluid samples. In-field sample analysis could benefit from the capability to use a finger prick of blood to measure drugs in whole blood at low cost and in a short time. Some studies may require specialized blood collection devices that can be used in remote areas. In this study, four different dried blood spot (DBS) devices are used with PS sources and tested for rapid quantification of imatinib and N-desmethyl-imatinib. A triple quadrupole mass spectrometer allows analyte detection with high sensitivity. Analytical figures of merit for the four devices are compared, and it is concluded that several of the novel devices successfully deploy DBS with PS and yield similar results to traditional manual PS methods. Clinical samples collected in a remote location were analyzed as a proof of concept for in-field blood collection and subsequent rapid laboratory analysis. Graphical abstract Dried blood spot analyis by paper spray ionization MS/MS for in field sample collection.
- Published
- 2017
- Full Text
- View/download PDF
3. Paper Analytic Device to Detect the Presence of Four Chemotherapy Drugs.
- Author
-
Smith M, Ashenef A, and Lieberman M
- Subjects
- Humans, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Chromatography, Thin Layer methods
- Abstract
A paper analytic device, the chemoPAD, was developed and validated to visually detect methotrexate, doxorubicin, cisplatin, and oxaliplatin at concentrations commonly found in injectable dosage forms. By testing residual solution after patient treatment, the chemoPAD can be used to monitor drug quality without restriction of patient access to medication. The chemoPAD is produced by wax printing on Ahlstrom paper to create separate reaction areas and deposits small amounts of chemicals to create color changes in response to different active pharmaceutical ingredients (APIs). This creates a unique color bar code to identify each medication. Internal validation studies show that the chemoPAD has excellent sensitivity and specificity to differentiate between samples of 100% and 0% API, which is the distinction relevant to the majority of reported falsified chemotherapy cases. The platinum-containing drugs, cisplatin and oxaliplatin, can be detected semiquantitatively. The cards can be read either visually by comparison with a standard image or by using computer image analysis. Dosage forms were collected from the Ethiopian health care system and analyzed with the chemoPAD followed by high-performance liquid chromatography. A substandard sample was discovered and reported to the Ethiopian Food Medicine and Healthcare Administration and Control Authority.
- Published
- 2018
- Full Text
- View/download PDF
4. Antioxidant and Anticancer Roles of a Novel Strain of Bacillus anthracis Isolated from Vermicompost Prepared from Paper Mill Sludge.
- Author
-
Ganguly RK, Midya S, and Chakraborty SK
- Subjects
- Animals, Antineoplastic Agents isolation & purification, Antioxidants isolation & purification, Humans, MCF-7 Cells, Oligochaeta, Sewage, Antineoplastic Agents pharmacology, Antioxidants pharmacology, Bacillus anthracis
- Abstract
Mass production of vermicompost using suitable species of earthworms and selecting target organic waste materials has appeared to be a great development in the realm of biotechnological research for the sustainable eco-management. Although, for the bioconversion of organic wastes to vermicompost, suitable earthworm species play major roles, a hoard of bacterial assemblages by virtue of production of different enzymes facilitate the process of vermicomposting. The present study has documented the roles of vermicompost associated bacteria in combating, preventing, and controlling of cancer so as to open a new vista not only in the field of vermitechnology but also on biomedical research. Earthworms' associated bacterial metabolic products having their unique physicochemical excellence have gained importance due to their roles as a facilitator of apoptosis (programed cell death in a MCF-7 cell line). The antioxidant and anticancer activities of ethyl acetate extracts' of vermicompost associated bacterium Bacillus anthracis were undertaken by antioxidant assay which revealed maximum DPPH radical scavenging effect (75.79 ± 5.41%) of the extracts' at 9 00 μ g ml-1. Furthermore, the crude extracts obtained from the same bacteria were found to decrease the activity of SOD (superoxide dismutase) with the increase in doses. MTT assay showed potent cytotoxic activity against human breast adenocarcinoma cells (MCF-7) with the IC50 value of 46.64 ± 0.79 μ g ml-1. It was further confirmed through Hoechst 33258 staining of nuclear fragmentation assay and DNA fragmentation analysis. Western blotting test has confirmed a downregulation of Akt upon application of crude extracts. Increase of SOD activity along with decrease of Akt level reflects that the mode of action is entirely PI-3K dependent. This study tends to indicate that B . anthracis isolated from vermicompost could be potentially explored for the development of new therapeutic agents, especially against cancer.
- Published
- 2018
- Full Text
- View/download PDF
5. Original research paper. Synthesis and antitumor activity of some novel thiophene, pyrimidine, coumarin, pyrazole and pyridine derivatives.
- Author
-
Albratty M, El-Sharkawy KA, and Alam S
- Subjects
- Antineoplastic Agents chemical synthesis, Cell Line, Tumor, Coumarins chemical synthesis, Humans, Pyrazoles chemical synthesis, Pyridines chemical synthesis, Pyrimidines chemical synthesis, Structure-Activity Relationship, Thiophenes chemical synthesis, Antineoplastic Agents pharmacology, Coumarins pharmacology, Pyrazoles pharmacology, Pyridines pharmacology, Pyrimidines pharmacology, Thiophenes pharmacology
- Published
- 2017
- Full Text
- View/download PDF
6. Original research paper. Hydrazinyldiene-chroman-2,4-diones in inducing growth arrest and apoptosis in breast cancer cells: Synergism with doxorubicin and correlation with physicochemical properties.
- Author
-
Ballazhi L, Imeri F, Jashari A, Popovski E, Stojković G, Dimovski AJ, Mikhova B, and Mladenovska K
- Subjects
- Antineoplastic Agents chemical synthesis, Breast Neoplasms metabolism, Breast Neoplasms pathology, Cell Movement drug effects, Coumarins chemical synthesis, Dose-Response Relationship, Drug, Drug Synergism, Female, Humans, Inhibitory Concentration 50, MCF-7 Cells, Molecular Structure, Permeability, Phosphorylation, Proto-Oncogene Proteins c-akt metabolism, Signal Transduction drug effects, Solubility, Structure-Activity Relationship, Antineoplastic Agents pharmacology, Antineoplastic Combined Chemotherapy Protocols pharmacology, Apoptosis drug effects, Breast Neoplasms drug therapy, Cell Proliferation drug effects, Coumarins pharmacology, Doxorubicin pharmacology, Drug Design, G2 Phase Cell Cycle Checkpoints drug effects
- Abstract
This study evaluates the effects of previously synthesized hydrazinyldiene-chroman-2,4-diones on cell proliferation and apoptosis, cell cycle distribution and migration capacity of MCF-7 breast cancer cells in synergy with doxorubicin. Physicochemical properties of the synthesized compounds were correlated with their structure and activity. Significant cell viability decrease in comparison with the effect of doxorubicin alone and the reference 4-hydroxycoumarin was observed when combination treatment comprising doxorubicin and the title compounds was applied. Synergistic effect with doxorubicin was also observed in down-regulation of phospho-Thr308Akt levels, confirming reduced proliferation and increased apoptosis. Combined treatment increased the percentage of cells arrested at the G2/M stage. Additive inhibition of cell migration was also observed, pointing to the possibility of reducing the risk of metastases. With their solubility profile and log D7.4, all the synthesized compounds follow Lipinski's rule of five for good permeability (absorption) potential.
- Published
- 2017
- Full Text
- View/download PDF
7. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).
- Author
-
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, Zamorano JL, Aboyans V, Achenbach S, Agewall S, Badimon L, Barón-Esquivias G, Baumgartner H, Bax JJ, Bueno H, Carerj S, Dean V, Erol Ç, Fitzsimons D, Gaemperli O, Kirchhof P, Kolh P, Lancellotti P, Lip GY, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Roffi M, Torbicki A, Vaz Carneiro A, and Windecker S
- Subjects
- Antineoplastic Agents therapeutic use, Cardiotoxicity, Congresses as Topic, Europe, Humans, Antineoplastic Agents adverse effects, Cardiology, Heart Diseases chemically induced, Neoplasms drug therapy, Practice Guidelines as Topic, Societies, Medical
- Published
- 2017
- Full Text
- View/download PDF
8. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
- Author
-
Bennett AV, Dueck AC, Mitchell SA, Mendoza TR, Reeve BB, Atkinson TM, Castro KM, Denicoff A, Rogak LJ, Harness JK, Bearden JD, Bryant D, Siegel RD, Schrag D, and Basch E
- Subjects
- Adult, Aged, Computers, Handheld, Cross-Over Studies, Female, Humans, Male, Middle Aged, National Cancer Institute (U.S.), Neoplasms psychology, Patient Outcome Assessment, Radiotherapy adverse effects, Reproducibility of Results, Self Report, Terminology as Topic, United States, Adverse Drug Reaction Reporting Systems classification, Antineoplastic Agents adverse effects, Chemoradiotherapy adverse effects, Drug-Related Side Effects and Adverse Reactions classification, Neoplasms therapy, Radiation Injuries classification
- Abstract
Background: PRO-CTCAE is a library of items that measure cancer treatment-related symptomatic adverse events (NCI Contracts: HHSN261201000043C and HHSN 261201000063C). The objective of this study is to examine the equivalence and acceptability of the three data collection modes (Web-enabled touchscreen tablet computer, Interactive voice response system [IVRS], and paper) available within the US National Cancer Institute (NCI) Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) measurement system., Methods: Participants (n = 112; median age 56.5; 24 % high school or less) receiving treatment for cancer at seven US sites completed 28 PRO-CTCAE items (scoring range 0-4) by three modes (order randomized) at a single study visit. Subjects completed one page (approx. 15 items) of the EORTC QLQ-C30 between each mode as a distractor. Item scores by mode were compared using intraclass correlation coefficients (ICC); differences in scores within the 3-mode crossover design were evaluated with mixed-effects models. Difficulties with each mode experienced by participants were also assessed., Results: 103 (92 %) completed questionnaires by all three modes. The median ICC comparing tablet vs IVRS was 0.78 (range 0.55-0.90); tablet vs paper: 0.81 (0.62-0.96); IVRS vs paper: 0.78 (0.60-0.91); 89 % of ICCs were ≥0.70. Item-level mean differences by mode were small (medians [ranges] for tablet vs. IVRS = -0.04 [-0.16-0.22]; tablet vs paper = -0.02 [-0.11-0.14]; IVRS vs paper = 0.02 [-0.07-0.19]), and 57/81 (70 %) items had bootstrapped 95 % CI around the effect sizes within +/-0.20. The median time to complete the questionnaire by tablet was 3.4 min; IVRS: 5.8; paper: 4.0. The proportion of participants by mode who reported "no problems" responding to the questionnaire was 86 % tablet, 72 % IVRS, and 98 % paper., Conclusions: Mode equivalence of items was moderate to high, and comparable to test-retest reliability (median ICC = 0.80). Each mode was acceptable to a majority of respondents. Although the study was powered to detect moderate or larger discrepancies between modes, the observed ICCs and very small mean differences between modes provide evidence to support study designs that are responsive to patient or investigator preference for mode of administration, and justify comparison of results and pooled analyses across studies that employ different PRO-CTCAE modes of administration., Trial Registration: NCT Clinicaltrials.gov identifier: NCT02158637.
- Published
- 2016
- Full Text
- View/download PDF
9. CNS Anticancer Drug Discovery and Development Conference White Paper.
- Author
-
Levin VA, Tonge PJ, Gallo JM, Birtwistle MR, Dar AC, Iavarone A, Paddison PJ, Heffron TP, Elmquist WF, Lachowicz JE, Johnson TW, White FM, Sul J, Smith QR, Shen W, Sarkaria JN, Samala R, Wen PY, Berry DA, and Petter RC
- Subjects
- Animals, Clinical Trials as Topic, Disease Models, Animal, Disease-Free Survival, Endpoint Determination, Humans, Treatment Outcome, Antineoplastic Agents therapeutic use, Central Nervous System Neoplasms drug therapy, Drug Discovery, Glioma drug therapy, Medulloblastoma drug therapy
- Abstract
Following the first CNS Anticancer Drug Discovery and Development Conference, the speakers from the first 4 sessions and organizers of the conference created this White Paper hoping to stimulate more and better CNS anticancer drug discovery and development. The first part of the White Paper reviews, comments, and, in some cases, expands on the 4 session areas critical to new drug development: pharmacological challenges, recent drug approaches, drug targets and discovery, and clinical paths. Following this concise review of the science and clinical aspects of new CNS anticancer drug discovery and development, we discuss, under the rubric "Accelerating Drug Discovery and Development for Brain Tumors," further reasons why the pharmaceutical industry and academia have failed to develop new anticancer drugs for CNS malignancies and what it will take to change the current status quo and develop the drugs so desperately needed by our patients with malignant CNS tumors. While this White Paper is not a formal roadmap to that end, it should be an educational guide to clinicians and scientists to help move a stagnant field forward., (© The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
10. Passing up paper: Electronic systems improve safety in chemotherapy ordering and management.
- Author
-
Coghill AS
- Subjects
- Humans, Neoplasms nursing, Nurse's Role, Oncology Nursing, Patient Safety, Workforce, Antineoplastic Agents therapeutic use, Medical Order Entry Systems, Medical Records Systems, Computerized, Neoplasms drug therapy
- Published
- 2014
11. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.
- Author
-
Aapro M, Bernard-Marty C, Brain EG, Batist G, Erdkamp F, Krzemieniecki K, Leonard R, Lluch A, Monfardini S, Ryberg M, Soubeyran P, and Wedding U
- Subjects
- Adult, Aged, Humans, Middle Aged, Neoplasms drug therapy, Anthracyclines adverse effects, Antineoplastic Agents adverse effects
- Abstract
Background: Comorbidities and risk factors likely to complicate treatment are common in elderly cancer patients. Anthracyclines remain the cornerstone of first-line therapy for non-Hodgkin's lymphoma (NHL) and metastatic and early breast cancer but can cause congestive heart failure. Elderly patients are at increased risk of this event and measures to reduce it should be considered., Methods: A committee of experts in breast cancer and NHL met under the auspices of the International Society for Geriatric Oncology to review the literature and make recommendations, based on level of evidence, for the assessment, treatment and monitoring of elderly patients requiring anthracyclines., Results and Recommendations: Use of anthracycline-based chemotherapy illustrates many of the dilemmas facing elderly cancer patients. Age in itself should not prevent access to potentially curative treatment or treatment that prolongs life or improves its quality. The risk of cardiotoxicity with conventional anthracyclines is increased by the following factors: an existing or history of heart failure or cardiac dysfunction; hypertension, diabetes and coronary artery disease; older age (independent of comorbidities and performance status); prior treatment with anthracyclines; higher cumulative dose of anthracyclines and short infusion duration. The fact that cumulative and irreversible cardiotoxicity is likely to be greater in this population than among younger patients calls for effective pretreatment screening for risk factors, rigorous monitoring of cardiac function and early intervention. Use of liposomal anthracycline formulations, prolonging the infusion time for conventional anthracyclines and cardioprotective measures should be considered. However, when treatment is being given with curative intent, care should be taken to ensure reduced cardiotoxicity is not achieved at the expense of efficacy.
- Published
- 2011
- Full Text
- View/download PDF
12. Papers with industry ties. Classic confounding conflicts.
- Author
-
Evans SJ
- Subjects
- Clinical Trials as Topic economics, Humans, Research Support as Topic, Antineoplastic Agents therapeutic use, Conflict of Interest, Drug Industry economics, Interprofessional Relations, Neoplasms drug therapy
- Published
- 2009
- Full Text
- View/download PDF
13. Hypersensitivity reactions to chemotherapy: an EAACI Position Paper
- Author
-
Patrizia Bonadonna, Emilio Alvarez-Cuesta, Adile Berna Dursun, Soledad Sanchez Sanchez, Mariana Castells, Josefina Cernadas, Mauro Pagani, Hamadi Sahar, Anca M. Chiriac, Ricardo Madrigal-Burgaleta, and Sevim Bavbek
- Subjects
Drug ,medicine.medical_specialty ,Allergy ,media_common.quotation_subject ,medicine.medical_treatment ,Immunology ,Provocation test ,Drug allergy ,Antineoplastic Agents ,Disease ,Drug Hypersensitivity ,Neoplasms ,Humans ,Immunology and Allergy ,Medicine ,Intensive care medicine ,Anaphylaxis ,Skin Tests ,media_common ,Desensitization (medicine) ,business.industry ,medicine.disease ,Desensitization, Immunologic ,Position paper ,business - Abstract
Chemotherapeutic drugs have been widely used in the treatment of cancer disease for about 70 years. The development of new treatments has not hindered their use, and oncologists still prescribe them routinely, alone or in combination with other antineoplastic agents. However, all chemotherapeutic agents can induce hypersensitivity reactions (HSRs), with different incidences depending on the culprit drug. These reactions are the third leading cause of fatal drug-induced anaphylaxis in the United States. In Europe, deaths related to chemotherapy have also been reported. In particular, most reactions are caused by platinum compounds, taxanes, epipodophyllotoxins and asparaginase. Despite their prevalence and relevance, the ideal pathways for diagnosis, treatment and prevention of these reactions are still unclear, and practice remains considerably heterogeneous with vast differences from center to center. Thus, the European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of Allergy and Clinical Immunology organized a task force to provide data and recommendations regarding the allergological work-up in this field of drug hypersensitivity reactions. This position paper aims to provide consensus on the investigation of HSRs to chemotherapeutic drugs and give practical recommendations for clinicians that treat these patients, such as oncologists, allergologists and internists. Key sections cover risk factors, pathogenesis, symptoms, the role of skin tests, in vitro tests, indications and contraindications of drug provocation tests and desensitization of neoplastic patients with allergic reactions to chemotherapeutic drugs. Statements, recommendations and unmet needs were discussed and proposed at the end of each section.
- Published
- 2021
14. Cancer nanomedicines: So many papers and so few drugs!
- Author
-
Venditto, Vincent J and Szoka, Francis C
- Subjects
Medical Biotechnology ,Biomedical and Clinical Sciences ,Cancer ,Bioengineering ,Orphan Drug ,Nanotechnology ,Biotechnology ,Rare Diseases ,5.1 Pharmaceuticals ,Development of treatments and therapeutic interventions ,Antineoplastic Agents ,Drug Carriers ,Drug Delivery Systems ,Humans ,Nanomedicine ,Neoplasms ,Camptothecin ,Liposomes ,Monoclonal antibodies ,Platinum therapy ,Polymers ,Pharmacology and Pharmaceutical Sciences ,Pharmacology & Pharmacy ,Pharmacology and pharmaceutical sciences - Abstract
This review identifies a timeline to nanomedicine anticancer drug approval using the business model of inventors, innovators and imitators. By evaluating the publication record of nanomedicine cancer therapeutics we identified a trend of very few publications prior to FDA approval. We first enumerated the publications related to cancer involving polymers, liposomes or monoclonal antibodies and determined the number of citations per publication as well as the number of published clinical trials among the publications. Combining these data with the development of specific nanomedicines, we are able to identify an invention phase consisting of seminal papers in basic science necessary for the development of a specific nanomedicine. The innovation phase includes the first report, the development and the clinical trials involving that nanomedicine. Finally, the imitation phase begins after approval when others ride the wave of success by using the same formulation for new drugs or using the same drug to validate other nanomedicines. We then focused our analysis on nanomedicines containing camptothecin derivatives, which are not yet approved including two polymers considered innovations and one liposomal formulation in the imitation phase. The conclusion that may be drawn from the analysis of the camptothecins is that approved drugs reformulated in polymeric and liposomal cancer nanomedicines have a more difficult time navigating through the approval process than the parent molecule. This is probably due to the fact that for most currently approved drugs, reformulating them in a nanocarrier provides a small increase in performance that large pharmaceutical companies do not consider being worth the time, effort and expense of development. It also appears that drug carriers have a more difficult path through the clinic than monoclonal antibodies. The added complexity of nanocarriers also deters their use to deliver new molecular entities. Thus, the new drug candidates that might be most improved by drug delivery in nanocarriers are not formulated in this fashion.
- Published
- 2013
15. Cytotoxicity of ZnO Paper against Cancer Cells.
- Author
-
Su-Yu Liao, Jing-Jenn Lin, Congo Tak-Shing Ching, and You-Lin Wu
- Subjects
CANCER cells ,GAS detectors ,ZINC oxide ,CELL survival ,ANTINEOPLASTIC agents ,CELL lines - Abstract
Paper incorporated with ZnO nanostructures (called ZnO paper) is a flexible substrate material with applications in many areas including UV detectors and gas sensors. In this work, we tested the cytotoxicity of ZnO paper against cancer cells. The ZnO paper was placed in culture media of different cancer cell lines including A549, H1299, and WI38 with and without the targeted anti-lung cancer drugs Iressa and Staurosporine, and cell viability was determined. We found that ZnO nanoparticles were cytotoxic to all the cell lines examined, and cell viability was further reduced by increasing the deposition time of these nanoparticles. In addition, cytotoxicity was enhanced when both the ZnO paper and the anticancer drugs were present in the culture media. Our experimental results indicate that ZnO paper can be used for cytotoxicity test and the development of future novel anticancer drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Developing a Drug Screening Platform: MALDI-Mass Spectrometry Imaging of Paper-Based Cultures
- Author
-
Amanda B. Hummon, Gabriel J. LaBonia, Julie C. McIntosh, Matthew R. Lockett, Matthew W. Boyce, and Fernando Tobias
- Subjects
Paper ,Drug ,Matrigel ,Chemistry ,Drug discovery ,media_common.quotation_subject ,010401 analytical chemistry ,Cell Culture Techniques ,Drug Evaluation, Preclinical ,Antineoplastic Agents ,Computational biology ,Paper based ,HCT116 Cells ,010402 general chemistry ,Mass spectrometry ,01 natural sciences ,Article ,Mass spectrometry imaging ,0104 chemical sciences ,Analytical Chemistry ,Matrix-assisted laser desorption/ionization ,In vivo ,Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization ,Humans ,media_common - Abstract
Many potential chemotherapeutics fail to reach patients. One of the key reasons is that compounds are tested during the drug discovery stage in two-dimensional (2D) cell cultures, which are often unable to accurately model in vivo outcomes. Three-dimensional (3D) in vitro tumor models are more predictive of chemotherapeutic effectiveness than 2D cultures, and thus, their implementation during the drug screening stage has the potential to more accurately evaluate compounds earlier, saving both time and money. Paper-based cultures (PBCs) are an emerging 3D culture platform in which cells suspended in Matrigel are seeded into paper scaffolds and cultured to generate a tissue-like environment. In this study, we demonstrate the potential of matrix-assisted laser desorption/ionization-mass spectrometry imaging with PBCs (MALDI-MSI-PBC) as a drug screening platform. This method discriminated regions of the PBCs with and without cells and/or drugs, indicating that coupling PBCs with MALDI-MSI has the potential to develop rapid, large-scale, and parallel mass spectrometric drug screens.
- Published
- 2019
17. Left ventricular mechanical dyssynchrony after chemotherapy in breast cancer patients with normal rest gated SPECT-MPI.
- Author
-
Derakhshan S, Ghaderi B, and Roshani D
- Subjects
- Humans, Female, Cardiotoxicity diagnostic imaging, Cardiotoxicity etiology, Cross-Sectional Studies, Mastectomy, Tomography, Emission-Computed, Single-Photon methods, Doxorubicin adverse effects, Breast Neoplasms drug therapy, Ventricular Dysfunction, Left diagnostic imaging, Myocardial Perfusion Imaging methods, Antineoplastic Agents
- Abstract
Objectives: Early diagnosis of chemotherapy-induced cardiotoxicity plays an important role in preventing heart failure. The main aim of our study was to assess left ventricular (LV) dyssynchrony measured by phase analysis of gated single-photon emission computed tomography (SPECT) as an early sign of cardiotoxicity after breast cancer chemotherapy., Methods: This cross-sectional study was conducted on patients with stage ≤ 3 breast cancer and no history of cardiovascular disease or diabetes. After mastectomy, the patients underwent rest gated SPECT myocardial perfusion imaging (MPI). Sixty patients with normal gated SPECT-MPI were selected and the imaging was performed after chemotherapy with doxorubicin, cyclophosphamide and paclitaxel. LV function and contractility parameters were extracted by QGS software and the results were compared with the t test method. The abnormality of at least one of the three phase analysis indices was considered as left ventricular dyssynchrony (LVD)., Results: The average LV end-systolic volume and ejection fraction (LVEF) before and after chemotherapy were (16.2 ± 8.0 ml and 21.6 ± 11.6 ml) and (73.4 ± 7.9% and 67.5 ± 9.2%) respectively, which showed a significant decrease (P < 0.05). In 2 patients (3.3%), the LVEF decreased to less than 50% after chemotherapy. The average parameters of left ventricular contractility before and after chemotherapy were, respectively, as follows: PHB (24.1 ± 7.5 and 33.8 ± 16.4), PSD (9.4 ± 6.1 and 5.7 ± 1.9) and entropy (28.9 ± 7.1 and 35.6 ± 9.7), which showed a significant increase (P < 0.05). LVD was observed in 14 patients (23.4%) after chemotherapy and prevalence of LVD was significantly higher in patients who had received a cumulative dose of doxorubicin of more than 400 mg/m
2 (P = 0.005). There was no relationship between age and body mass index with the incidence of LVD after chemotherapy (P > 0.05)., Conclusion: Using phase analysis of gated SPECT-MPI, chemotherapy-induced LVD was seen in a significant number of patients with breast cancer, especially with a high cumulative dose of doxorubicin. LVD might indicate chemotherapy-induced cardiotoxicity before LVEF becomes abnormal., (© 2024. The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.)- Published
- 2024
- Full Text
- View/download PDF
18. Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology
- Author
-
Denise Hilfiker-Kleiner, Michael Hallek, Roman Pfister, Tienush Rassaf, Diana Lüftner, Johann Bauersachs, Ulrich Neudorf, Lorenz H. Lehmann, Stephan von Haehling, Oliver J. Müller, Johannes Backs, Matthias Totzeck, Andreas Hochhaus, and Carsten Bokemeyer
- Subjects
medicine.medical_specialty ,Side effect ,Cancer therapy ,medicine.medical_treatment ,Medizin ,Antineoplastic Agents ,030204 cardiovascular system & hematology ,German ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Consensus Paper ,Risk Factors ,Internal medicine ,Germany ,Neoplasms ,medicine ,Chemotherapy ,Humans ,Adverse effect ,Cardiotoxicity ,Hematology ,Radiotherapy ,business.industry ,General Medicine ,Survivorship programs ,Combined Modality Therapy ,language.human_language ,Radiation therapy ,Cardio-oncology ,Cardiovascular Diseases ,030220 oncology & carcinogenesis ,language ,Cardiology ,Quality of Life ,Immunotherapy ,Cardiology and Cardiovascular Medicine ,business - Abstract
The acute and long-lasting side effects of modern multimodal tumour therapy significantly impair quality of life and survival of patients afflicted with malignancies. The key components of this therapy include radiotherapy, conventional chemotherapy, immunotherapy and targeted therapies. In addition to established tumour therapy strategies, up to 30 new therapies are approved each year with only incompletely characterised side effects. This consensus paper discusses the risk factors that contribute to the development of a potentially adverse reaction to tumour therapy and, in addition, defines specific side effect profiles for different treatment groups. The focus is on novel therapeutics and recommendations for the surveillance and treatment of specific patient groups.
- Published
- 2020
19. Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper
- Author
-
Fabio Gomes, Nicolò Matteo Luca Battisti, Tiana Kordbacheh, Andrea Luciani, Alastair Greystoke, M. Kiderlen, Melisa L. Wong, and Radiotherapy
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Immunosenescence ,medicine.medical_treatment ,Antineoplastic Agents ,Review Article ,03 medical and health sciences ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,medicine ,Humans ,Lung cancer ,Immune Checkpoint Inhibitors ,030304 developmental biology ,0303 health sciences ,Chemotherapy ,Clinical Trials as Topic ,business.industry ,Immunotherapy ,Radioimmunotherapy ,medicine.disease ,Clinical trial ,Radiation therapy ,Geriatric oncology ,030220 oncology & carcinogenesis ,Position paper ,Non small cell ,business ,Non-small-cell lung cancer - Abstract
Immunotherapy with checkpoint inhibitors against programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1) has been implemented in the treatment pathway of patients with non-small cell lung cancer (NSCLC) from locally advanced disease to the metastatic setting. This approach has resulted in improved survival and a more favourable toxicity profile when compared with chemotherapy. Following the successful introduction of single-agent immunotherapy, current clinical trials are focusing on combination treatments with chemotherapy or radiotherapy or even other immunotherapeutic agents. However, most of the data available from these trials are derived from, and therefore might be more applicable to younger and fitter patients rather than older and often frail lung cancer real-world patients. This article provides a detailed review of these immunotherapy agents with a focus on the data available regarding older NSCLC patients and makes recommendations to fill evidence gaps in this patient population.
- Published
- 2020
20. Hypersensitivity reactions to biologicals: An EAACI position paper
- Author
-
Alessandra Vultaggio, Soledad Sanchez-Sanchez, Mauro Pagani, Ricardo Madrigal-Burgaleta, Mariana Castells, Emilio Alvarez-Cuesta, Adile Berna Dursun, Sevim Bavbek, and Sahar Hamadi
- Subjects
medicine.medical_specialty ,Biological Products ,High prevalence ,business.industry ,Immunology ,Treatment options ,Antineoplastic Agents ,Precision medicine ,Optimal management ,Unmet needs ,Clinical Practice ,Drug Hypersensitivity ,Desensitization, Immunologic ,Immunology and Allergy ,Medicine ,Position paper ,Humans ,Precision Medicine ,business ,Intensive care medicine - Abstract
Biologicals are crucial targeted therapeutic agents in oncological, immunological, and inflammatory diseases, and their use in clinical practice is broadening. In recent years, the spread of Personalized Precision Medicine has facilitated a proliferation of new treatment options, especially biologicals. Consequently, biologicals are now among the drugs that most frequently cause hypersensitivity reactions (HSRs). Patients can develop HSRs to these agents during the first-lifetime exposure or after repeated exposure, and these HSRs can be potentially life-threatening or limit therapeutic options. Despite the relatively high prevalence, the underlying mechanisms of these HSRs remain obscure, and the optimal management pathways are still a matter of discussion. In this Position Paper, the authors will provide evidence-based recommendations for diagnosing and managing HSRs to biologicals. Additionally, the document defines unmet needs as an opportunity to shape future research.
- Published
- 2021
21. A Functionalized Paper Strip-Based Platform for Rapid Detection of Anticancer Drug Concentrations.
- Author
-
Stojanović, Goran M., Kojić, Tijana, Simić, Mitar, Radovanović, Milan, Panić, Sanja, Srdić, Vladimir V., Vukmirović, Saša, Ellison, Gaewyn, and Al-Salami, Hani
- Subjects
ANTINEOPLASTIC agents ,MULTIWALLED carbon nanotubes ,METHOTREXATE ,COPPER foil ,ELECTRIC circuits - Abstract
This article presents a compact, low-cost, robust, and flexible test platform for determining the concentration of drugs in fluids. This device is based on a PVC foil card containing copper conductive foils in which disposable paper test strips are inserted. The paper test strips are overlaid with deposition of multiwalled carbon nanotubes (MWCNTs) acting as a sensing layer. When a paper test strip is inserted into the test card, the conductive path between two copper lines is established. A drop of test fluid on the sensing MWCNT layer changes the conductivity in a concentration-dependent manner, enabling calculation of the drug concentration after measurement of the electrical resistance at the copper terminals. An equivalent electrical circuit was also proposed to model the response of the fabricated sensor. It was shown that model parameters are dependent on the concentration of the cytostatic drug methotrexate. Additionally, the fabricated sensor demonstrated the ability to differentiate the same concentration of methotrexate and cyclophosphamide. The complete readout electronics and polynomial transfer function for calculating drug concentrations were also developed and are presented. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
22. Integrated blood and organ profile analysis to evaluate ameliorative effects of kaempferol on 5-fluorouracil-induced toxicity.
- Author
-
Sharma A, Chorawala MR, Rawal RM, and Shrivastava N
- Subjects
- Animals, Kaempferols pharmacology, Apoptosis, Fluorouracil pharmacology, Colorectal Neoplasms pathology, Antineoplastic Agents adverse effects
- Abstract
Colorectal cancer (CRC) treatment strategies encompass a triad of medical interventions: surgery, radiotherapy, and chemotherapy. Among these, the use of chemotherapy, specifically 5-fluorouracil (5-FU), has become a cornerstone in CRC management. However, it is imperative to explore novel approaches that harness the synergistic potential of chemotherapy agents alongside adjunctive compounds to mitigate the severe adverse effects that often accompany treatment. In light of this pressing need, this study focuses on evaluating Kaempferol (KMP) in combination with 5-FU in a DMH-induced CRC animal model, scrutinizing its impact on haematological indices, organ health, and gastrointestinal, hepatotoxic, and nephrotoxic effects. Remarkably, KMP demonstrated haemato-protective attributes and exerted an immunomodulatory influence, effectively counteracting 5-FU-induced damage. Furthermore, organ assessments affirm the safety profile of the combined treatments while suggesting KMP's potential role in preserving the structural integrity of the intestine, and spleen. Histopathological assessments unveiled KMP's capacity to ameliorate liver injury and mitigate CRC-induced renal impairment. These multifaceted findings underscore KMP's candidacy as a promising adjunctive therapeutic option for CRC, underlining the pivotal need for personalized therapeutic strategies that concurrently optimize treatment efficacy and safeguard organ health. KMP holds tremendous promise in elevating the paradigm of CRC management., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
23. Teclistamab salvage therapy for multiple myeloma relapse after allogeneic hemopoietic stem cell transplant: A case report.
- Author
-
Zaja F, Lucchini E, Poiani M, Sbisà E, Mohamed S, De Bellis E, Caizzi M, Palmieri C, Loiacono S, Granzotto M, Sirianni F, and De Sabbata G
- Subjects
- Humans, Salvage Therapy, Neoplasm Recurrence, Local, Transplantation, Autologous, Multiple Myeloma drug therapy, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents therapeutic use
- Published
- 2024
- Full Text
- View/download PDF
24. Screening Estrogen Receptor Modulators in a Paper-Based Breast Cancer Model
- Author
-
Nathan A. Whitman, Zhi-Wei Lin, Thomas J. Diprospero, Matthew R. Lockett, and Julie C. McIntosh
- Subjects
Paper ,0301 basic medicine ,Drug Evaluation, Preclinical ,Estrogen receptor ,Antineoplastic Agents ,Breast Neoplasms ,Enzyme-Linked Immunosorbent Assay ,Article ,Analytical Chemistry ,Structure-Activity Relationship ,03 medical and health sciences ,Transactivation ,0302 clinical medicine ,Estrogen Receptor Modulators ,In vivo ,Tumor Cells, Cultured ,Humans ,Gene ,Cell Proliferation ,Dose-Response Relationship, Drug ,Chemistry ,Estrogen Receptor alpha ,Estrogens ,Paper based ,Breast Cancer Model ,030104 developmental biology ,030220 oncology & carcinogenesis ,MCF-7 Cells ,Cancer research ,Female ,Estrogen Receptor Antagonists ,Drug Screening Assays, Antitumor ,Estrogen receptor alpha - Abstract
The health risks associated with acute and prolonged exposure to estrogen receptor (ER) modulators has led to a concerted effort to identify and prioritize potential disruptors present in the environment. ER agonists and antagonists are identified with end-point assays, quantifying changes in cellular proliferation or gene transactivation in monolayers of estrogen receptor alpha expressing (ER+) cells upon exposure. While these monolayer cultures can be prepared, dosed, and analyzed in a highly parallelized manner, they are unable to predict the potencies of ER modulators in vivo accurately. Physiologically relevant model systems that better predict tissue- or organ-level responses are needed. To address this need, we describe here a screening platform capable of quantitatively assessing ER modulators in 96 chemically isolated 3D cultures. These cultures are supported in wax-patterned paper scaffolds whose design has improved performance and throughput over previously described paper-based setups. To highlight the potential of paper-based cultures for toxicity screens, we measured the potency of known ER modulators with a luciferase-based reporter assay. We also quantified the proliferation and invasion of two ER+ cell lines in the presence of estradiol. Despite the inability of the current setup to better predict in vivo potencies of ER modulators than monolayer cultures, the results demonstrate the potential of this platform to support increasingly complex and physiologically relevant tissue-like structures for environmental chemical risk assessment.
- Published
- 2018
25. Onco-gynecologic surgery in the COVID-19 era: Risks and precautions-A position paper from FRANCOGYN, SCGP, SFCO, and SFOG
- Author
-
Pierre Collinet, Vincent Lavoué, Cherif Akladios, Laurence Gladieff, Fabrice Lecuru, and Jean Marc Classe
- Subjects
medicine.medical_specialty ,2019-20 coronavirus outbreak ,Consensus ,Coronavirus disease 2019 (COVID-19) ,Genital Neoplasms, Female ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pneumonia, Viral ,MEDLINE ,Antineoplastic Agents ,Article ,Betacoronavirus ,Gynecologic Surgical Procedures ,Obstetrics and Gynaecology ,Preoperative Care ,Medicine ,Humans ,Intensive care medicine ,Personal protective equipment ,Pandemics ,Personal Protective Equipment ,Societies, Medical ,Surgeons ,Withholding Treatment ,biology ,business.industry ,SARS-CoV-2 ,Obstetrics and Gynecology ,COVID-19 ,biology.organism_classification ,Telemedicine ,Anesthesiologists ,Occupational Diseases ,Reproductive Medicine ,Position paper ,Female ,France ,business ,Coronavirus Infections - Published
- 2020
26. Transition from laboratory to clinic in cancer treatment. Abstracts of symposium papers.
- Subjects
- Animals, Drug Evaluation, Drug Evaluation, Preclinical, Humans, Research, Antineoplastic Agents therapeutic use, Neoplasms drug therapy
- Published
- 1981
- Full Text
- View/download PDF
27. Quality of life after cytotoxic chemotherapy: discussion paper.
- Author
-
Priestman TJ
- Subjects
- Breast Neoplasms drug therapy, Breast Neoplasms psychology, Female, Humans, Male, Medroxyprogesterone adverse effects, Medroxyprogesterone analogs & derivatives, Medroxyprogesterone Acetate, Neoplasms psychology, Self-Assessment, Surveys and Questionnaires, Antineoplastic Agents adverse effects, Neoplasms drug therapy, Quality of Life
- Published
- 1984
- Full Text
- View/download PDF
28. Twenty-fifth annual general meeting of the British Association for Cancer Research. Abstracts of invited and profferred papers.
- Subjects
- Clinical Trials as Topic, Humans, Antineoplastic Agents therapeutic use, Neoplasms drug therapy
- Published
- 1984
- Full Text
- View/download PDF
29. Optimal chemotherapy for ovarian carcinoma: discussion paper.
- Author
-
Lambert HE
- Subjects
- Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy, Drug Administration Schedule, Female, Hormones therapeutic use, Humans, Quality of Life, Antineoplastic Agents therapeutic use, Ovarian Neoplasms drug therapy
- Published
- 1984
- Full Text
- View/download PDF
30. Determination of mammalian cell (strain HeLa) inhibition by an agar diffusion technic. II. Paper chromatographic methods.
- Author
-
SIMINOFF P and HURSKY VS
- Subjects
- Animals, Humans, Agar, Antineoplastic Agents, HeLa Cells, Mammals
- Published
- 1960
31. SUMMARY OF INFORMAL DISCUSSIONS ON THE ROLE OF PYRIMIDINE ANTAGONISTS FOLLOWING PAPERS BY DR. PRUSOFF AND DR. CALABRESI.
- Author
-
WELCH AD
- Subjects
- Antimetabolites, Antineoplastic Agents, Floxuridine, Fluorouracil, Idoxuridine, Neoplasms therapy, Nucleosides, Pyrimidines
- Published
- 1963
32. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
- Author
-
Pier Luigi Zinzani, Stefano Fagiuoli, Paolo Ghia, Antonio Cuneo, Giovanni Barosi, Alfredo Marzano, Romano Danesi, Pierluigi Viale, Marco Montillo, Venerino Poletti, Cuneo, Antonio, Barosi, Giovanni, Danesi, Romano, Fagiuoli, Stefano, Ghia, Paolo, Marzano, Alfredo, Montillo, Marco, Poletti, Venerino, Viale, Pierluigi, Zinzani, Pier Luigi, Cuneo, A, Barosi, G, Danesi, R, Fagiuoli, S, Ghia, P, Marzano, A, Montillo, M, Poletti, V, Viale, P, and Zinzani, P
- Subjects
Oncology ,Cancer Research ,Adverse events ,chronic lymphocytic leukemia ,follicular lymphoma ,idelalisib ,Chronic lymphocytic leukemia ,adverse event ,Follicular lymphoma ,Review ,Antineoplastic Agent ,0302 clinical medicine ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,Cytochrome P-450 CYP3A ,Drug Interactions ,Disease management (health) ,Lymphoma, Follicular ,Disease Management ,Hematology ,General Medicine ,Colitis ,Algorithm ,Aldehyde Oxidase ,Drug Interaction ,030220 oncology & carcinogenesis ,Idelalisib ,Algorithms ,Human ,Diarrhea ,medicine.medical_specialty ,Reviews ,Antineoplastic Agents ,Quinazolinone ,NO ,03 medical and health sciences ,Internal medicine ,medicine ,Animals ,Humans ,Clinical significance ,Adverse effect ,Purine ,Quinazolinones ,Pneumonitis ,adverse events ,Antineoplastic Combined Chemotherapy Protocol ,Animal ,business.industry ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Purines ,Position paper ,business ,Coliti ,030215 immunology - Abstract
The introduction of new therapeutic agents in chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), including the new kinase inhibitor idelalisib, has changed the therapeutic landscape of these diseases. However, the use of idelalisib is associated with a peculiar profile of side effects, which require an optimization of the current approach to prophylaxis and supportive treatment. Moving from the recognition that the abovementioned issue represents an unmet need in CLL and FL, a multidisciplinary panel of experts was convened to produce a consensus document aiming to provide practical recommendations for the management of the side effects during idelalisib therapy for CLL and FL. The present publication represents a consensus document from a series of meetings held during 2017. The Panel generated clinical key questions using the criterion of clinical relevance through a Delphi process and explored 4 domains, ie, diarrhea/colitis, transaminitis, pneumonitis, and infectious complications. Using the consensus method, the Panel was able to shape recommendations which may assist hematologist to minimize adverse events and guarantee adherence to treatment in patients with CLL and FL candidate to receive idelalisib.
- Published
- 2019
33. Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper
- Author
-
P. Ferrari, E. Tuveri, Marco Gallo, Stella D'Oronzo, Antongiulio Faggiano, V. Adinolfi, Romano Danesi, Stefania Gori, A. Natalicchio, M.C. Zatelli, L. Morviducci, Antonella Argentiero, A. Russo, S. Acquati, Nicola Silvestris, Monica Montagnani, P. Di Bartolo, Giordano D. Beretta, Francesco Giorgino, Silvestris N., Argentiero A., Natalicchio A., D'Oronzo S., Beretta G.D., Acquati S., Adinolfi V., Di Bartolo P., Danesi R., Faggiano A., Ferrari P., Gallo M., Gori S., Morviducci L., Russo A., Tuveri E., Zatelli M.C., Montagnani M., and Giorgino F.
- Subjects
obesity ,Cancer Research ,medicine.medical_specialty ,pharmacokinetic parameters ,Consensus ,BSA ,cancer drug dosing ,Population ,chemotherapy dose ,Antineoplastic Agents ,Review ,Overweight ,NO ,Dosing schedules ,Neoplasms ,Physicians ,Internal medicine ,Humans ,Medicine ,Dosing ,LS4_3 ,education ,Body surface area ,education.field_of_study ,business.industry ,Cancer ,Cytotoxic chemotherapy ,medicine.disease ,Oncology ,Position paper ,Obesity ,medicine.symptom ,business - Abstract
Most anticancer molecules are administered in body-size-based dosing schedules, bringing up unsolved issues regarding pharmacokinetic data in heavy patients. The worldwide spread of obesity has not been matched by improved methods and strategies for tailored drug dosage in this population. The weight or body surface area (BSA)-based approaches may fail to fully reflect the complexity of the anthropometric features besides obesity in cancer patients suffering from sarcopenia. Likewise, there is a lack of pharmacokinetic data on obese patients for the majority of chemotherapeutic agents as well as for new target drugs and immunotherapy. Therefore, although the available findings point to the role of dose intensity in cancer treatment, and support full weight-based dosing, empirical dose capping often occurs in clinical practice in order to avoid toxicity. Thus a panel of experts of the Associazione Italiana Oncologia Medica (AIOM), Associazione Medici Diabetologi (AMD), Società Italiana Endocrinologia (SIE), and Società Italiana Farmacologia (SIF), provides here a consensus statement for appropriate cytotoxic chemotherapy and new biological cancer drug dosing in obese patients., Highlights • The worldwide spread of obesity is an emerging challenge also in cancer patients • Weight or BSA-based approaches do not adequately address the critical issue of optimal dosing for cancer drugs under obesity • Empirical dose capping is often employed in clinical practice to avoid toxicities among overweight and obese patients • There is a lack of clinical and pharmacokinetic studies in this population • Clinical practice recommendations should guide suitable dosing of cytotoxic and biological cancer drugs in obese patients
- Published
- 2021
34. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group
- Author
-
Seok Jin Kim, Dok Hyun Yoon, Deok Hwan Yang, Bing Xu, Koji Izutsu, Lim Soon Thye, Tong Yu Lin, Junning Cao, Tsai Yun Chen, Won Seog Kim, and Yok-Lam Kwong
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Asia ,medicine.medical_treatment ,Antineoplastic Agents ,Review ,Lymphoma, Mantle-Cell ,Hematopoietic stem cell transplantation ,Disease ,Guidelines ,lcsh:RC254-282 ,chemistry.chemical_compound ,Maintenance therapy ,Chemoimmunotherapy ,Internal medicine ,medicine ,Humans ,Molecular Biology ,Mantle cell lymphoma ,business.industry ,lcsh:RC633-647.5 ,Hematopoietic Stem Cell Transplantation ,Disease Management ,Hematology ,lcsh:Diseases of the blood and blood-forming organs ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Lymphoma ,Radiation therapy ,Treatment ,chemistry ,Ibrutinib ,Immunotherapy ,business - Abstract
Background Mantle cell lymphoma (MCL) is a B cell malignancy that can be aggressive and with a poor prognosis; the clinical course is heterogeneous. The epidemiology of MCL in Asia is not well documented but appears to comprise 2–6% of all lymphoma cases based on available data, with variation observed between countries. Although international guidelines are available for the treatment of MCL, there is a lack of published data or guidance on the clinical characteristics and management of MCL in patient populations from Asia. This paper aims to review the available treatment and, where clinical gaps exist, provide expert consensus from the Asian Lymphoma Study Group (ALSG) on appropriate MCL management in Asia. Body Management strategies for MCL are patient- and disease stage-specific and aim to achieve balance between efficacy outcomes and toxicity. For asymptomatic patients with clearly indolent disease, observation may be an appropriate strategy. For stage I/II disease, following international guidelines is appropriate, which include either a short course of conventional chemotherapy followed by consolidated radiotherapy, less aggressive chemotherapy regimens, or a combination of these approaches. For advanced disease, the approach is based on the age and fitness of the patient. For young, fit patients, the current practice for induction therapy differs across Asia, with cytarabine having an important role in this setting. Hematopoietic stem cell transplantation (HSCT) may be justified in selected patients because of the high relapse risk. In elderly patients, specific chemoimmunotherapy regimens available in each country/region are a treatment option. For maintenance therapy after first-line treatment, the choice of approach should be individualized, with cost being an important consideration within Asia. For relapsed/refractory disease, ibrutinib should be considered as well as other follow-on compounds, if available. Conclusion Asian patient-specific data for the treatment of MCL are lacking, and the availability of treatment options differs between country/region within Asia. Therefore, there is no clear one-size-fits-all approach and further investigation on the most appropriate sequence of treatment that should be considered for this heterogeneous disease.
- Published
- 2020
35. Spontaneous formation of tumor spheroid on a hydrophilic filter paper for cancer stem cell enrichment.
- Author
-
Fu, Jing Jing, Zhou, Ying, Shi, Xiao Xiao, Kang, Yue Jun, Lu, Zhi Song, Li, Yuan, Li, Chang Ming, and Yu, Ling
- Subjects
- *
HYDROPHILIC surfaces , *CANCER stem cells , *CELLULOSE , *ANTINEOPLASTIC agents , *BIOCOMPATIBILITY - Abstract
Graphical abstract Highlights • Spontaneously spheroids formation on hydrophilic paper with regular culture medium. • Underlying the mechanism of spontaneously tumor spheroids formation on filter paper. • Elevated expression of CSCs markers on paper-grown cells, indicating CSCs potential. • Increased CSC-marker positive cells highlights the potential in enrichment of CSCs. Abstract Emerging evidence has demonstrated that cancer stem cells (CSCs) play critical roles in tumor invasion, metastasis and recurrence. The specific targeting capability on CSCs is of high importance for the development of effective anti-tumor therapeutics. However, isolation, enrichment and cultivation of these special and rare groups of tumor cells for in vitro analyses is a nontrivial job and requires particular culture medium and environmental control. Herein, we established a low-cost and efficient method for CSC enrichment by culturing prostate cancer cells on a hydrophilic filter paper. We found that tumor spheroids could form spontaneously on a pristine filter paper solely with regular cell culture medium. The paper-grown cells had elevated expression of putative CSC markers, indicating increased stemness of the cancer cells. Moreover, increased resistance of the chemotherapeutic drug doxorubicin was observed on the formed CSC spheroids compared to regular culture. The properties of the filter paper were characterized to investigate the underlying mechanism behind the promoted tumor spheroid formation. The obtained results suggested that the excellent hydrophilicity of the cellulose fibers retarded the hydrophobic interaction-mediated cell anchoring on the cellulose fibers, while the limited space/niche between fibers promoted the aggregation of cells. In addition, biocompatible paper-based materials are able to realize convenient assembly of tissue-like structures for developing in vitro disease models or organs-on-paper applications. Therefore, hydrophilic filter papers could be a low-cost material for construction of various assay platforms for isolating and enriching CSCs, screening anti-tumor drugs, and constructing tumor models in vitro. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
36. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology
- Author
-
Jutta Bergler-Klein, Peter P. Rainer, Markus Wallner, Marc-Michael Zaruba, Jakob Dörler, Armin Böhmer, Tamara Buchacher, Maria Frey, Christopher Adlbrecht, Rupert Bartsch, Mariann Gyöngyösi, and Ursula-Maria Fürst
- Subjects
Heart Failure ,Angiotensins ,Cardiology ,Angiotensin-Converting Enzyme Inhibitors ,Antineoplastic Agents ,Breast Neoplasms ,Stroke Volume ,General Medicine ,Cardiotoxicity ,Troponin ,Ventricular Function, Left ,Austria ,Humans ,Female ,Natriuretic Peptides ,Immune Checkpoint Inhibitors ,Biomarkers - Abstract
SummarySurvival in cancer is continuously improving due to evolving oncological treatment. Therefore, cardiovascular short-term and long-term side effects gain crucial importance for overall outcome. Cardiotoxicity not only presents as heart failure, but also as treatment-resistant hypertension, acute coronary ischemia with plaque rupture or vasospasm, thromboembolism, arrhythmia, pulmonary hypertension, diastolic dysfunction, acute myocarditis and others. Recent recommendations have proposed baseline cardiac risk assessment and surveillance strategies. Major challenges are the availability of monitoring and imaging resources, including echocardiography with speckle tracking longitudinal strain (GLS), serum biomarkers such as natriuretic peptides (NT-proBNP) and highly sensitive cardiac troponins. This Austrian consensus encompasses cardiotoxicity occurrence in frequent antiproliferative cancer drugs, radiotherapy, immune checkpoint inhibitors and cardiac follow-up considerations in cancer survivors in the context of the Austrian healthcare setting. It is important to optimize cardiovascular risk factors and pre-existing cardiac diseases without delaying oncological treatment. If left ventricular ejection fraction (LVEF) deteriorates during cancer treatment (from >10% to 15% change in GLS), early initiation of cardioprotective therapies (angiotensin-converting enzyme inhibitors, angiotensin or beta receptor blockers) is recommended, and LVEF should be reassessed before discontinuation. Lower LVEF cut-offs were recently shown to be feasible in breast cancer patients to enable optimal anticancer treatment. Interdisciplinary cardio-oncology cooperation is pivotal for optimal management of cancer patients.
- Published
- 2021
37. Towards a high throughput impedimetric screening of chemosensitivity of cancer cells suspended in hydrogel and cultured in a paper substrate
- Author
-
Kin Fong Lei, Tai-Kun Liu, and Ngan-Ming Tsang
- Subjects
Paper ,Cell Survival ,Cell ,Biomedical Engineering ,Biophysics ,Cell Culture Techniques ,Antineoplastic Agents ,02 engineering and technology ,01 natural sciences ,Hydrogel, Polyethylene Glycol Dimethacrylate ,3D cell culture ,Cell Line, Tumor ,Neoplasms ,Electrochemistry ,medicine ,Electric Impedance ,Humans ,Doxorubicin ,Viability assay ,Etoposide ,Chemistry ,010401 analytical chemistry ,Substrate (chemistry) ,General Medicine ,Equipment Design ,Hep G2 Cells ,021001 nanoscience & nanotechnology ,Molecular biology ,0104 chemical sciences ,Cell biology ,High-Throughput Screening Assays ,medicine.anatomical_structure ,Cell culture ,Cancer cell ,Drug Screening Assays, Antitumor ,0210 nano-technology ,Biotechnology ,medicine.drug - Abstract
In order to achieve high predictive value of cell chemosensitivity test for clinical efficacy, cancer cells were suggested to be encapsulated and cultured in hydrogel to mimic the natural microenvironment of tumors. However, handling 3D cells/hydrogel culture construct is tedious and cellular response is difficult to be quantitatively analyzed. In the current study, a novel platform for conducting 3D cell culture and analyzing cell viability has been developed towards a high throughput drug screening. Cells encapsulated in the hydrogel were cultured in the microwells of a paper substrate. The substrate was then immersed in the culture medium containing drug for 2 days. At 24 and 48h during the culture course, the paper substrate was placed on the measurement electrodes for conducting the impedance measurement in order to quantify the cell viability in the hydrogel. Cell viability of two human hepatoma cell lines (Huh7 and Hep-G2) was quantitatively investigated under the treatment of two drugs (doxorubicin and etoposide). The results represented by IC50 values revealed that Huh7 cells had a higher drug resistance than Hep-G2 cells and doxorubicin had a higher efficacy than etoposide for treating hepatocellular carcinoma. The current work has demonstrated a high throughput, convenient, and quantitative platform for the investigation of chemosensitivity of cells cultured in the 3D environment.
- Published
- 2017
38. Conversion from paper to electronic acute care chemotherapy orders
- Author
-
Gerald Offei-nkansah and Lindsey B. Amerine
- Subjects
medicine.medical_specialty ,Pharmacist ,Pharmacy ,Antineoplastic Agents ,Cancer Care Facilities ,Pharmacists ,030226 pharmacology & pharmacy ,Workflow ,03 medical and health sciences ,0302 clinical medicine ,Medication Reconciliation ,Professional Role ,Multidisciplinary approach ,Electronic health record ,Acute care ,Physicians ,medicine ,Electronic Health Records ,Humans ,030212 general & internal medicine ,Pharmacology ,Patient Care Team ,Inpatients ,business.industry ,Health Policy ,medicine.disease ,Clinical pharmacy ,Schedule (workplace) ,Medical emergency ,business ,Pharmacy Service, Hospital - Abstract
Purpose UNC Medical Center converted to an electronic health record (EHR) in 2014. This conversion allowed for the transition of paper chemotherapy orders to be managed electronically. This article describes the process for converting inpatient paper chemotherapy orders into the new EHR in a safe and effective manner. Summary A collaborative interdisciplinary approach to the EHR transition enabled our organization to move from using paper chemotherapy orders to fully electronic chemotherapy treatment plans in both ambulatory and acute care areas. Active chemotherapy orders for acute care inpatients were reviewed and transcribed by two oncology pharmacists in the cancer hospital prior to being signed by an attending physician. The newly input orders were independently verified by two pharmacists in the cancer hospital inpatient pharmacy. Nurse review of the signed and verified treatment plans, along with reconciliation of the medication administration record ensured a safe transition to the new EHR workflow. Providers benefit from the ability to review treatment plans remotely, track changes, and include supportive medications in one consolidated location. The coordinated team effort allowed for a smooth transition with minimal interruptions to patient care. Conclusion The pharmacist-led, multidisciplinary conversion to electronic chemotherapy orders was safe, accurate, and occurred ahead of schedule for the EHR go-live. Advance communication and planning around scheduled inpatient admissions helped to minimize the impact of the transition from paper to electronic treatment plans. Both pharmacist and physician engagement were necessary to ensure a smooth transition for active inpatient treatment plans.
- Published
- 2020
39. Comparison of paper spray mass spectrometry analysis of dried blood spots from devices used for in-field collection of clinical samples
- Author
-
Kristina R. Kesely, Karen E. Yannell, R. Graham Cooks, Huynh Dinh Chien, and Candice B. Kissinger
- Subjects
Paper ,Analyte ,Analytical chemistry ,Antineoplastic Agents ,010402 general chemistry ,01 natural sciences ,Biochemistry ,Piperazines ,Analytical Chemistry ,Limit of Detection ,Tandem Mass Spectrometry ,Humans ,Dried Blood Spot Testing ,Ambient ionization ,Blood Specimen Collection ,Chromatography ,Chemistry ,010401 analytical chemistry ,Selected reaction monitoring ,Equipment Design ,0104 chemical sciences ,Dried blood spot ,Triple quadrupole mass spectrometer ,Imatinib mesylate ,Benzamides ,Imatinib Mesylate ,Sample collection ,Drug Monitoring - Abstract
Paper spray (PS) is an ambient ionization technique applicable to ionizing analytes from untreated dried biofluid samples. In-field sample analysis could benefit from the capability to use a finger prick of blood to measure drugs in whole blood at low cost and in a short time. Some studies may require specialized blood collection devices that can be used in remote areas. In this study, four different dried blood spot (DBS) devices are used with PS sources and tested for rapid quantification of imatinib and N-desmethyl-imatinib. A triple quadrupole mass spectrometer allows analyte detection with high sensitivity. Analytical figures of merit for the four devices are compared, and it is concluded that several of the novel devices successfully deploy DBS with PS and yield similar results to traditional manual PS methods. Clinical samples collected in a remote location were analyzed as a proof of concept for in-field blood collection and subsequent rapid laboratory analysis. Graphical abstract Dried blood spot analyis by paper spray ionization MS/MS for in field sample collection.
- Published
- 2016
40. Platin desensitizations in thoracic malignancies and risk factors for breakthrough reactions.
- Author
-
Buhari GK, Kalkan İK, Ateş H, Bahçecioğlu SN, Demir Ş, Yeşilkaya S, Solak GTV, Aksu K, and Erkekol FÖ
- Subjects
- Humans, Carboplatin adverse effects, Cisplatin adverse effects, Retrospective Studies, Desensitization, Immunologic methods, Risk Factors, Skin Tests methods, Epinephrine therapeutic use, Antineoplastic Agents adverse effects, Drug Hypersensitivity diagnosis, Drug Hypersensitivity epidemiology, Thoracic Neoplasms epidemiology, Thoracic Neoplasms chemically induced, Thoracic Neoplasms complications, Hypersensitivity complications
- Abstract
Although platin desensitization is a safe and effective alternative for patients with hypersensitivity reactions (HSRs), sometimes breakthrough reactions (BTRs) can be encountered. However, data about the risk factors for BTRs are limited. The aim of this study is to define the outcomes of desensitization, the characteristics of BTRs, and to identify the risk factors for BTRs with platins in thoracic malignancies. This is a retrospective report of patients with thoracic malignancies who underwent platin desensitization. Patients' demographics, initial HSR characteristics, skin test results, desensitization outcomes, and BTR characteristics were recorded. Thirty-three lung cancer and 14 malignant pleural mesothelioma (MPM) patients were included in the study. The culprit drug was cisplatin in 29 and was carboplatin in 18 patients. Skin test positivity was 43.5% with cisplatin, 50% with carboplatin, and it was found to be higher if the interval between the initial HSR and skin testing (ST) was ˃20 days (p = 0.027). One hundred and five desensitization courses were performed. Twenty-two patients had 33 BTRs. Skin test positivity was higher in the BTR-positive group (p = 0.025). BTRs (18.2%; n = 6) were more severe than initial HSR. In the case of epinephrine administration during initial HSR, epinephrine administration during the first BTR was found to be more (p = 0.036). The target dose was achieved in 92.4% of desensitization courses. The number of previous platin infusions ≥10 was found to be an independent risk factor for BTR development (p = 0.036 OR:17.641, 95% CI: 1.211-256.971). Identification of risk factors for BTR will guide appropriate management and desensitization approaches for platin HSRs., Competing Interests: The authors declare no potential conflicts of interest with respect to research, authorship, and/or publication of this article.
- Published
- 2023
- Full Text
- View/download PDF
41. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)
- Author
-
Zamorano, JL, Lancellotti, P, Rodriguez Muñoz, D, Aboyans, V, Asteggiano, R, Galderisi, M, Habib, G, Lenihan, DJ, Lip, GY, Lyon, AR, Lopez Fernandez, T, Mohty, D, Piepoli, MF, Tamargo, J, Torbicki, A, Suter, TM, Achenbach, S, Agewall, S, Badimon, L, Barón-Esquivias, G, Baumgartner, H, Bax, JJ, Bueno, H, Carerj, S, Dean, V, Erol, Ç, Fitzsimons, D, Gaemperli, O, Kirchhof, P, Kolh, P, Nihoyannopoulos, P, Ponikowski, P, Roffi, M, Vaz Carneiro, A, Windecker, S, Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), University of Zurich, Zamorano, Jose Luis, Centre Hospitalier Universitaire de Liège (CHU-Liège), Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Università degli studi di Napoli Federico II, Unité de Recherche sur les Maladies Infectieuses Tropicales Emergentes (URMITE), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS), British Heart Foundation, Action Against Cancer, Zamorano, Jose Lui, Lancellotti, Patrizio, Rodriguez Muñoz, Daniel, Aboyans, Victor, Asteggiano, Riccardo, Galderisi, Maurizio, Habib, Gilbert, Lenihan, Daniel J., Lip, Gregory Y. H., Lyon, Alexander R., Lopez Fernandez, Teresa, Mohty, Dania, Piepoli, Massimo F., Tamargo, Juan, Torbicki, Adam, Suter, Thomas M., Achenbach, Stephan, Agewall, Stefan, Badimon, Lina, Barón Esquivias, Gonzalo, Baumgartner, Helmut, Bax, Jeroen J., Bueno, Héctor, Carerj, Scipione, Dean, Veronica, Erol, Çetin, Fitzsimons, Donna, Gaemperli, Oliver, Kirchhof, Paulu, Kolh, Philippe, Nihoyannopoulos, Petro, Ponikowski, Piotr, Roffi, Marco, Vaz Carneiro, António, Windecker, Stephan, Lenihan, Daniel J, Lip, Gregory Y. H, Lyon, Alexander R, Piepoli, Massimo F, University of Naples Federico II = Università degli studi di Napoli Federico II, Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, and Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Vascular Endothelial Growth Factor A ,Angiotensin receptor ,Cardiac & Cardiovascular Systems ,cardio-oncology ,medicine.medical_treatment ,myocardial dysfunction ,030204 cardiovascular system & hematology ,ANTHRACYCLINE-INDUCED CARDIOMYOPATHY ,chemotherapy ,Coronary artery disease ,0302 clinical medicine ,RENAL-CELL CARCINOMA ,Authors/Task Force Members ,Cancer Survivors ,Neoplasms ,Natriuretic peptide ,610 Medicine & health ,early detection ,ComputingMilieux_MISCELLANEOUS ,Societies, Medical ,HER2-POSITIVE BREAST-CANCER ,TRASTUZUMAB-INDUCED CARDIOTOXICITY ,Chemotherapy regimen ,3. Good health ,Europe ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,CHEMOTHERAPY-INDUCED CARDIOTOXICITY ,Practice Guidelines as Topic ,cardiovascular system ,Cardiology ,surveillance ,10209 Clinic for Cardiology ,cancer therapy ,CORONARY-ARTERY-DISEASE ,ESC Committee for Practice Guidelines (CPG) ,ischaemia ,Immunotherapy ,Cardiology and Cardiovascular Medicine ,Life Sciences & Biomedicine ,arrhythmias ,Arrhythmia ,Artery ,Cardiovascular toxicity ,medicine.medical_specialty ,Heart Diseases ,medicine.drug_class ,Advisory Committees ,Cancer therapy ,Early detection ,Antineoplastic Agents ,[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery ,1102 Cardiovascular Medicine And Haematology ,2705 Cardiology and Cardiovascular Medicine ,European Society of Cardiology ,03 medical and health sciences ,LEFT-VENTRICULAR DYSFUNCTION ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Internal medicine ,medicine ,TYROSINE KINASE INHIBITORS ,Humans ,cardiovascular diseases ,Intensive care medicine ,ACUTE LYMPHOBLASTIC-LEUKEMIA ,Cardiotoxicity ,Science & Technology ,CONGESTIVE-HEART-FAILURE ,Radiotherapy ,business.industry ,Arrhythmias ,Cardio-oncology ,Chemotherapy ,Ischaemia ,Myocardial dysfunction ,Surveillance ,Cancer ,10181 Clinic for Nuclear Medicine ,Congresses as Topic ,medicine.disease ,Radiation therapy ,Cardiovascular System & Hematology ,Cardiovascular System & Cardiology ,Position paper ,business ,human activities ,Document Reviewers - Abstract
2-D : two-dimensional 3-D : three-dimensional 5-FU : 5-fluorouracil ACE : angiotensin-converting enzyme ARB : angiotensin II receptor blocker ASE : American Society of Echocardiography BNP : B-type natriuretic peptide CABG : coronary artery bypass graft CAD : coronary artery
- Published
- 2016
42. Abstracts of papers presented at the 2005 collegiate meetings
- Subjects
Rhodes College ,Tennessee State University ,Homeopathy -- Materia medica and therapeutics ,Antineoplastic agents ,Brain tumors ,Therapeutics ,Cardiac patients ,Antimitotic agents ,Science and technology - Abstract
EASTERN REGION SOUTHERN ADVENTIST UNIVERSITY COLLEGEDALE, TENNESSEE DEMONSTRATION OF VACUUM DISTILLATION/DEMONSTRATION OF DISTILLATION OF DEET. Lindsy Collins and Robin Breeden, Walters State Community College, Morristown, Tennessee. Student prepared DEET was [...]
- Published
- 2005
43. Paper Analytic Device to Detect the Presence of Four Chemotherapy Drugs
- Author
-
Madeline Smith, Ayenew Ashenef, and Marya Lieberman
- Subjects
Active ingredient ,Cisplatin ,Cancer Research ,medicine.medical_specialty ,business.industry ,Sample (material) ,Computer image ,Antineoplastic Agents ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,lcsh:RC254-282 ,Dosage form ,Oxaliplatin ,Oncology ,Chemotherapy Drugs ,Color changes ,Internal medicine ,Original Reports ,medicine ,Humans ,Chromatography, Thin Layer ,business ,medicine.drug - Abstract
A paper analytic device, the chemoPAD, was developed and validated to visually detect methotrexate, doxorubicin, cisplatin, and oxaliplatin at concentrations commonly found in injectable dosage forms. By testing residual solution after patient treatment, the chemoPAD can be used to monitor drug quality without restriction of patient access to medication. The chemoPAD is produced by wax printing on Ahlstrom paper to create separate reaction areas and deposits small amounts of chemicals to create color changes in response to different active pharmaceutical ingredients (APIs). This creates a unique color bar code to identify each medication. Internal validation studies show that the chemoPAD has excellent sensitivity and specificity to differentiate between samples of 100% and 0% API, which is the distinction relevant to the majority of reported falsified chemotherapy cases. The platinum-containing drugs, cisplatin and oxaliplatin, can be detected semiquantitatively. The cards can be read either visually by comparison with a standard image or by using computer image analysis. Dosage forms were collected from the Ethiopian health care system and analyzed with the chemoPAD followed by high-performance liquid chromatography. A substandard sample was discovered and reported to the Ethiopian Food Medicine and Healthcare Administration and Control Authority.
- Published
- 2018
44. A newly isolated strain of Halomonas sp. (HA1) exerts anticancer potential via induction of apoptosis and G 2 /M arrest in hepatocellular carcinoma (HepG2) cell line.
- Author
-
El-Garawani IM, El-Sabbagh SM, Abbas NH, Ahmed HS, Eissa OA, Abo-Atya DM, Khalifa SAM, and El-Seedi HR
- Subjects
- Antineoplastic Agents isolation & purification, Cell Division drug effects, Cell Extracts isolation & purification, DNA Breaks, Single-Stranded, Drug Screening Assays, Antitumor, Gene Expression Regulation, Neoplastic drug effects, Hep G2 Cells, Humans, Lymphocytes drug effects, Neoplasm Proteins biosynthesis, Neoplasm Proteins genetics, RNA, Messenger biosynthesis, RNA, Messenger genetics, RNA, Neoplasm biosynthesis, RNA, Neoplasm genetics, Ribotyping, Up-Regulation drug effects, Antineoplastic Agents pharmacology, Apoptosis drug effects, Carcinoma, Hepatocellular pathology, Cell Extracts pharmacology, G2 Phase Cell Cycle Checkpoints drug effects, Halomonas chemistry, Liver Neoplasms pathology
- Abstract
Marine bacterial strains are of great interest for their ability to produce secondary metabolites with anticancer potentials. Isolation, identification, characterization and anticancer activities of isolated bacteria from El-Hamra Lake, Wadi El-Natrun (Egypt) were the objectives of this study. The isolated bacteria were identified as a moderately halophilic alkaliphilic strain. Ethyl acetate extraction was performed and identified by liquid chromatography-mass spectrophotometry (LC-MS-MS) and nuclear magnetic resonance analysis (NMR). Cytotoxicity of the extract was assessed on the HepG2 cell line and normal human peripheral lymphocytes (HPBL) in vitro. Halomonas sp. HA1 extract analyses revealed anticancer potential. Many compounds have been identified including cyclo-(Leu-Leu), cyclo-(Pro-Phe), C17-sphinganine, hexanedioic acid, bis (2-ethylhexyl) ester, surfactin C14 and C15. The extract exhibited an IC
50 of 68 ± 1.8 μg/mL and caused marked morphological changes in treated HepG2 cells. For mechanistic anticancer evaluation, 20 and 40 µg/mL of bacterial extract were examined. The up-regulation of apoptosis-related genes' expression, P53, CASP-3, and BAX/BCL-2 at mRNA and protein levels proved the involvement of P53-dependant mitochondrial apoptotic pathway. The anti-proliferative properties were confirmed by significant G2 /M cell cycle arrest and PCNA down-regulation in the treated cells. Low cytotoxicity was observed in HPBL compared to HepG2 cells. In conclusion, results suggest that the apoptotic and anti-proliferative effects of Halomonas sp. HA1 extract on HepG2 cells can provide it as a candidate for future pharmaceutical industries.- Published
- 2020
- Full Text
- View/download PDF
45. European Society for Medical Oncology (ESMO) position paper on supportive and palliative care.
- Author
-
Jordan, K, Aapro, M, Kaasa, S, Ripamonti, C I, Scotté, F, Strasser, F, Young, A, Bruera, E, Herrstedt, J, and Keefe, D
- Subjects
- *
PALLIATIVE treatment , *ANTINEOPLASTIC agents , *CANCER treatment , *INDIVIDUALIZED medicine , *QUALITY of life - Abstract
Oncology has come a long way in addressing patients' quality of life, together with developing surgical, radio-oncological and medical anticancer therapies. However, the multiple and varying needs of patients are still not beingmet adequately as part of routine cancer care. Supportive and palliative care interventions should be integrated, dynamic, personalised and based on best evidence. They should start at the time of diagnosis and continue through to end-of-life or survivorship. ESMO is committed to excellence in all aspects of oncological care during the continuum of the cancer experience. Following the 2003 ESMO stand on supportive and palliative care (Cherny N, Catane R, Kosmidis P. ESMO takes a stand on supportive and palliative care. Ann Oncol 2003; 14(9): 1335-1337), this position paper highlights the evolving and growing gap between the needs of cancer patients and the actual provision of care. The concept of patient-centred cancer care is presented along with key requisites and areas for further work. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
46. The structural conformation of the tachykinin domain drives the anti-tumoural activity of an octopus peptide in melanoma BRAF V600E .
- Author
-
Moral-Sanz J, Fernandez-Rojo MA, Colmenarejo G, Kurdyukov S, Brust A, Ragnarsson L, Andersson Å, Vila SF, Cabezas-Sainz P, Wilhelm P, Vela-Sebastián A, Fernández-Carrasco I, Chin YKY, López-Mancheño Y, Smallwood TB, Clark RJ, Fry BG, King GF, Ramm GA, Alewood PF, Lewis RJ, Mulvenna JP, Boyle GM, Sanchez LE, Neely GG, Miles JJ, and Ikonomopoulou MP
- Subjects
- Adenosine Triphosphate, Animals, Calcium, Cell Line, Tumor, Humans, Mice, Mutation, Octopodiformes chemistry, Peptides pharmacology, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins B-raf therapeutic use, RNA, Messenger, Reactive Oxygen Species, Tachykinins genetics, Tachykinins therapeutic use, Zebrafish genetics, Antineoplastic Agents pharmacology, Melanoma drug therapy, Melanoma pathology
- Abstract
Background and Purpose: Over past decades, targeted therapies and immunotherapy have improved survival and reduced the morbidity of patients with BRAF-mutated melanoma. However, drug resistance and relapse hinder overall success. Therefore, there is an urgent need for novel compounds with therapeutic efficacy against BRAF-melanoma. This prompted us to investigate the antiproliferative profile of a tachykinin-peptide from the Octopus kaurna, Octpep-1 in melanoma., Experimental Approach: We evaluated the cytotoxicity of Octpep-1 by MTT assay. Mechanistic insights on viability and cellular damage caused by Octpep-1 were gained via flow cytometry and bioenergetics. Structural and pharmacological characterization was conducted by molecular modelling, molecular biology, CRISPR/Cas9 technology, high-throughput mRNA and calcium flux analysis. In vivo efficacy was validated in two independent xerograph animal models (mice and zebrafish)., Key Results: Octpep-1 selectively reduced the proliferative capacity of human melanoma BRAF
V600E -mutated cells with minimal effects on fibroblasts. In melanoma-treated cells, Octpep-1 increased ROS with unaltered mitochondrial membrane potential and promoted non-mitochondrial and mitochondrial respiration with inefficient ATP coupling. Molecular modelling revealed that the cytotoxicity of Octpep-1 depends upon the α-helix and polyproline conformation in the C-terminal region of the peptide. A truncated form of the C-terminal end of Octpep-1 displayed enhanced potency and efficacy against melanoma. Octpep-1 reduced the progression of tumours in xenograft melanoma mice and zebrafish., Conclusion and Implications: We unravel the intrinsic anti-tumoural properties of a tachykinin peptide. This peptide mediates the selective cytotoxicity in BRAF-mutated melanoma in vitro and prevents tumour progression in vivo, providing a foundation for a therapy against melanoma., (© 2022 British Pharmacological Society.)- Published
- 2022
- Full Text
- View/download PDF
47. Antifertility Effect of Bougainvillea spectabilis or Paper Flower.
- Author
-
Anisa Ghogar and Wannee Jiraungkoorskul
- Subjects
- *
BOUGAINVILLEA , *BIRTH control , *TRADITIONAL medicine , *MEDICINAL plants , *ANTINEOPLASTIC agents - Abstract
Bougainvillea spectabilis (Family: Nyctaginaceae), commonly referred to as Great Bougainvillea or Paper Flower, is one of the traditional medicinal plants with potential antifertility activity. The aqueous extract and decoction of this plant have been used as fertility control among the tribal people in many countries. Furthermore, it has been shown to possess anticancer, antidiabetic, antihepatotoxic, anti-inflammatory, antihyperlipidemic, antimicrobial, antioxidant, and antiulcer properties. Its phytoconstituents such as alkaloids, essential oils, favonoids, glycosides, oxalates, phenolics, phlobotannins, quinones, saponins, tannins, and terpenoids were reported as the basis of its efficacious therapeutic properties. The other important constituents which contribute to the remedial properties are bougainvinones, pinitol, quercetagetin, quercetin, and terpinolene. Published information on the antifertility property of B. spectabilis was gathered by the use of different database platforms including Google Scholar, ScienceDirect, PubMed, SciFinder, and Scopus. These database platforms were used to provide an up-to-date review on its importance. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
48. Studies on the mode of action of 2,2'-anhydro-1- -D-arabinofuranosylcytosine.
- Author
-
Wang MC, Sharma RA, and Bloch A
- Subjects
- Adenosine Triphosphate metabolism, Animals, Antineoplastic Agents metabolism, Carbon Isotopes, Carcinoma, Ehrlich Tumor drug therapy, Carcinoma, Ehrlich Tumor enzymology, Cell-Free System, Chromatography, Paper, Cytarabine metabolism, Deamination, Deoxycytidine metabolism, Drug Resistance, Electrophoresis, Paper, Escherichia coli enzymology, Female, Hydrogen-Ion Concentration, Hydrolysis, Leukemia L1210 drug therapy, Leukemia L1210 enzymology, Mice, Mice, Inbred Strains, Oxidative Phosphorylation, Antineoplastic Agents pharmacology, Cytarabine pharmacology
- Published
- 1973
49. Focus on anticancer therapy-induced cardiotoxicity from the perspective of oncologists.
- Author
-
Liu B, Wang Y, Lyu D, and Ma F
- Subjects
- Humans, Cardiotoxicity etiology, Antineoplastic Agents adverse effects, Oncologists, Neoplasms drug therapy
- Published
- 2022
- Full Text
- View/download PDF
50. Oral targeted therapy dose adaptation in older patients with cancer: A real-life French cohort.
- Author
-
Carbasse C, Leenhardt F, Jacot W, Perrier C, Pinguet F, and Viala M
- Subjects
- Administration, Oral, Afatinib therapeutic use, Aged, Aged, 80 and over, Everolimus therapeutic use, Humans, Indoles, Pyrroles, Retrospective Studies, Sorafenib therapeutic use, Sunitinib therapeutic use, Treatment Outcome, Antineoplastic Agents, Carcinoma, Renal Cell drug therapy, Kidney Neoplasms drug therapy
- Abstract
Introduction: Oral targeted therapies (OTTs) are widely used for cancer management. However, there is no consensus on OTT dose adaptation in older patients with cancer., Methods: This noninterventional, retrospective study was a real-life assessment of dose adaptation for six OTTs (afatinib, everolimus, palbociclib, pazopanib, sorafenib and sunitinib), at baseline and during treatment, and the reasons for the changes, in ≥70-year-old patients treated between February 2016 and August 2019. Data were compared with univariate models fitted with all variables., Results: Among the 986 patients treated with OTT, the group of ≥70-year-old patients (n = 122) received afatinib (15.6%), everolimus (14.8%), palbociclib (50.8%), pazopanib (9.8%), sorafenib (5.8%) or sunitinib (3.2%). At baseline, the prescribed OTT dose was adapted (reduction) in 29% of ≥70-year-old patients (35/122). These 35 patients were significantly older (mean age 80 vs 74 years, P < .001), and more frequently had a performance status score ≥2 (P < .01) than the other patients (n = 87). In the standard dose group, higher toxicity grades (P = .18) and subsequent dose reduction (41% of patients, 36/87) tended to be more frequent compared with the baseline adapted dose group (26%, 9/35, P = .1). At the study end, 53% of patients in the whole cohort (65/122) were taking a lower dose than the recommended one., Conclusion: At OTT initiation, dose was adapted in 29% of older adults with cancer, rarely after a formal oncogeriatric evaluation (6.5% of all patients). In the absence of recommendations, clinical studies are needed to evaluate the efficacy and safety of baseline OTT dose reduction in older adults with cancer., (© 2022 British Pharmacological Society.)
- Published
- 2022
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.